ReportsAssessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial☆,☆☆,★,★★,♢
Section snippets
Patients and methods
A total of 90 consenting Caucasian patients were enrolled into this randomized, controlled, 2-center, investigator-masked, balanced parallel-group design study of 9 months duration. This study was reviewed and approved by each center's institutional review board before initiation.
Patients had to be between 18 and 85 years of age and have a minimum of 5 and a maximum of 25 visible actinic keratoses. There was no minimum number requirement for solar lentigines. The minimum size of individual
Results
A total of 90 patients, 45 from each center, were included in the study and 83 patients completed 9 months of treatment. All patients presented with actinic keratoses and approximately 75% of patients also had at least 1 solar lentigo. All of the patients were Caucasian, with the majority (79%) having skin phototypes I and II. Only 1 patient in the adapalene 0.3% group discontinued because of skin irritation and the other 6 patients discontinued because of non-treatment-related events. Patient
Discussion
Topical application of adapalene gel 0.1% and 0.3% was well tolerated and improved actinic keratoses and lentigines. In addition, retrospective evaluation of clinical photographs revealed that adapalene gel also improved signs of photoaging, particularly mottled hyperpigmentation and fine wrinkles, during a treatment period of 9 months' duration.
Adapalene gel use resulted in a modest reduction in the number of actinic keratosis in a dose-dependent manner, whereas vehicle gel led to an increase
Acknowledgements
The authors thank John T. Headington, MD, for histologic evaluation of biopsy specimens; Harrold Carter for medical photography; and Kristy Andrew for editorial assistance.
References (28)
Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”)
J Am Acad Dermatol
(2000)- et al.
Analysis of p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers
Cancer Lett
(1994) Clinical presentation of actinic keratoses and squamous cell carcinoma
J Am Acad Dermatol
(2000)- et al.
Tretinoin emollient cream: a new therapy for photodamaged skin
J Am Acad Dermatol
(1992) Topical tretinoin in actinic keratosis and basal cell carcinoma
J Am Acad Dermatol
(1986)- et al.
Pharmacology and chemistry of adapalene
J Am Acad Dermatol
(1997) - et al.
Retinoic acid induction of human cellular retinoic acid-binding protein-II gene transcription is mediated by retinoic acid receptor-retinoid X receptor heterodimers bound to one far upstream retinoic acid-responsive element with 5-based pair spacing
J Biol Chem
(1994) - et al.
c-fos is required for malignant progression of skin tumors
Cell
(1995) - et al.
Retinoic acid is a potent inhibitor of inducible pigmentation in murine and hamster melanoma cell lines
J Invest Dermatol
(1990) - et al.
Histopathology of the skin
The actinic keratosis: a perspective and update
Dermatol Surg
Actinic keratosis is squamous cell carcinoma
South Med J
Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective
Arch Dermatol
Aging and photoaging of the skin: observations at the cellular and molecular level
Br J Dermatol
Cited by (94)
Topical Retinoids
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionCutaneous squamous cell carcinoma: Management of advanced and high-stage tumors
2018, Journal of the American Academy of DermatologyImmunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives
2023, Clinical, Cosmetic and Investigational DermatologyA Review of Cutaneous Diseases Observed in Solid Organ Transplant Recipients
2022, Journal of Clinical and Aesthetic Dermatology
- ☆
Supported by Galderma Corp, Fort Worth, Texas.
- ☆☆
Disclosure: Dr Kang has served as an ad hoc paid consultant to and Dr Griffiths is a paid consultant to Galderma Corporation.
- ★
Reprint requests: Sewon Kang, MD, University of Michigan Medical Center, Department of Dermatology, 1910A Alfred Taubman Center, Ann Arbor, MI 48109-0314. E-mail: [email protected].
- ★★
*Dr Griffiths is currently at the Dermatology Centre, The University of Manchester, Salford, Manchester, UK.
- ♢
0190-9622/2003/$30.00 + 0